Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | THRA | P10827 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | VNN1 | O95497 | 1/20 | 0.42 |
| ▸ | MMP2 | P08253 | 2/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | FLT3 | P36888 | 1/20 | 0.41 |
| ▸ | MMP3 | P08254 | 1/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.41 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.41 |
| ▸ | LSS | P48449 | 3/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | HSD17B14 | Q9BPX1 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4094642 | 0.86 | CHRNA7 (0.49) | ALDH1A1KDM4EMAPTVNN1HSD17B14 | |
| SCHEMBL3956887 | 0.82 | KDM4E (0.48) | ALDH1A1KDM4EMAPTVNN1HSD17B14 | |
| SCHEMBL3945625 | 0.81 | PSMB1 (0.52) | KDM4EESR1FLT3HRH3 | |
| SCHEMBL3954103 | 0.78 | CHEK2 (0.43) | VNN1 | |
| SCHEMBL5804959 | 0.78 | PKM (0.45) | ALDH1A1KDM4EMAPTVNN1ESR1 | |
| SCHEMBL4079787 | 0.77 | HSD17B14 (0.55) | ALDH1A1MAPTVNN1HSD17B14MEN1 | |
| SCHEMBL3950626 | 0.76 | HSD17B14 (0.51) | VNN1ESR1HSD17B14MEN1KMT2A | |
| SCHEMBL8134642 | 0.73 | KDM4E (0.69) | ALDH1A1KDM4ETHRAESR1BCHE | |
| SCHEMBL4087894 | 0.71 | HRH3 (0.59) | ALDH1A1KDM4EMAPTMMP2ESR1 | |
| SCHEMBL8134959 | 0.71 | ALDH1A1 (0.62) | ALDH1A1KDM4ETHRAMAPTBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2065383-A1 | Indazole compounds and methods of use thereof as protein kinase inhibitors | Signal Pharmaceuticals, Inc. (US) | 2009-06-03 | — | — | EP | disclosed |
| US-20090099178-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF | BHAGWAT SHRIPAD S | 2009-04-16 | — | — | US | disclosed |
| EP-1692128-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF AS PROTEIN KINASE INHIBITORS | Signal Pharmaceuticals LLC (US) | 2006-08-23 | — | — | EP | disclosed |
| US-20060004043-A1 | Indazole compounds and methods of use thereof | BHAGWAT SHRIPAD S | 2006-01-05 | — | — | US | disclosed |
| WO-2005051942-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF AS PROTEIN KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099178-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF | WNT3, WNT3A, WNK3 | ALDH1A1 3165/4885KDM4E 3468/4885THRA 2484/4885 |
| US-20060004043-A1 | Indazole compounds and methods of use thereof | WNT3, WNT3A, WNK3 | ALDH1A1 3055/4885KDM4E 3359/4885THRA 2421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.